The federal government has a bit of a backward stance on marijuana. It labels it a Schedule I drug, a designation that means it has no notable medical benefits, making it difficult for scientists to study its uses.
Yesterday, Sen. Orrin Hatch (R-Utah) introduced a bill to hopefully change that. Titled the Marijuana Effective Drug Study Act of 2017, it aims to relax the federal restrictions on studying medical marijuana. In his statement introducing the bill, he’s got puns.
He’s got lots of puns.
Today, Senator Orrin Hatch (R-UT) introduced the Marijuana Effective Drug Study Act of 2017, or MEDS Act, to improve the process for conducting scientific research on marijuana as a safe and effective medical treatment. In introducing this legislation, Senator Hatch was joined by Senator Schatz (D-HI) and cosponsors Senator Chris Coons (D-DE), Senator Cory Gardner (R-CO), and Senator Thom Tillis (R-NC).
“It’s high time to address research into medical marijuana,” Hatch said. “Our country has experimented with a variety of state solutions without properly delving into the weeds on the effectiveness, safety, dosing, administration, and quality of medical marijuana. All the while, the federal government strains to enforce regulations that sometimes do more harm than good. To be blunt, we need to remove the administrative barriers preventing legitimate research into medical marijuana, which is why I’ve decided to roll out the MEDS Act.
“I urge my colleagues to join Senator Schatz and me in our joint effort to help thousands of Americans suffering from a wide-range of diseases and disorders. In a Washington at war with itself, I have high hopes that this bipartisan initiative can be a kumbaya moment for both parties.”
Can you count all those jokes? We’ve got “high times,” “into the weeds,” strains to enforce,” and “to be blunt,” among others.
Hatch took to the floor of the Senate to talk about his bill.
Man’s got jokes.
H/T Kelly Cohen